Osteal Therapeutics

Osteal Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative products for the treatment of infections following artificial joint replacement surgeries. The company utilizes high concentrations of locally delivered antibiotics to treat biofilms formed by post-operative infections in artificial joints. This treatment approach not only rapidly addresses the infection but also minimizes side effects on other organs caused by systemic use of high-dose antibiotics. Osteal adopts a low-risk development strategy, which involves the innovative localized application of approved drugs with long-term safety and efficacy. The company’s lead product, VT-X7, is currently in Phase II clinical development and is intended for treating severe complications after joint replacement surgery—periprosthetic joint infection (PJI).